In vitro synergy of clindamycin and aminoglycosides against Chlamydia trachomatis.
The importance of Chlamydia trachomatis as an etiologic agent in the development of pelvic inflammatory disease (PID) is well documented. Although there are numerous antimicrobial agents that are effective against C. trachomatis, one of the most frequent combinations that is used to treat PID is clindamycin and gentamicin. The efficacy of clindamycin as the sole treatment for chlamydial infections has been questioned. In fact, the Centers for Disease Control (Atlanta, Ga.) has recommended the use of doxycycline following clindamycin and gentamicin treatment of PID confirmed or suspected to be caused by C. trachomatis. This study was designed to determine whether there is any synergistic in vitro activity between clindamycin and gentamicin or tobramycin on inhibition of C. trachomatis replication. In this experiment, the MIC of clindamycin decreased two- to threefold when an aminoglycoside was added. This occurred even though aminoglycosides by themselves had essentially no effect against C. trachomatis. The mechanism of this interaction is uncertain.
Pearlman
M D
MD
Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas 77030.
Faro
S
S
Riddle
G D
GD
Tortolero
G
G
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002692:Chlamydia trachomatis / Q000187:drug effects*; D002981:Clindamycin / Q000494:pharmacology*; D004357:Drug Synergism; D005839:Gentamicins / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D014031:Tobramycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D002981:Clindamycin; D014031:Tobramycin